Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.39 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | AR | P10275 | 11/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | PGR | P06401 | 2/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29212775 | 0.78 | KDM4E (0.38) | ALDH1A1KDM4EIMPDH2IMPDH1USP2 | |
| SCHEMBL7961132 | 0.71 | ALDH1A1 (0.48) | ALDH1A1KDM4EIMPDH2IMPDH1USP2 | |
| SCHEMBL748238 | 0.70 | — | — | |
| SCHEMBL161217 | 0.70 | CA2 (0.36) | ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL315488 | 0.68 | KDM4E (0.35) | ALDH1A1KDM4E | |
| SCHEMBL745940 | 0.68 | — | — | |
| SCHEMBL2034789 | 0.68 | GAA (0.41) | ALDH1A1KDM4EIMPDH2IMPDH1USP2 | |
| SCHEMBL2067460 | 0.67 | KDM4E (0.34) | ALDH1A1KDM4EIMPDH2IMPDH1USP2 | |
| SCHEMBL6672925 | 0.66 | CA1 (0.39) | ALDH1A1KDM4EIMPDH2IMPDH1USP2 | |
| SCHEMBL26259810 | 0.66 | IMPDH2 (0.48) | ALDH1A1KDM4EIMPDH2IMPDH1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070254917-A1 | INTRACELLULAR RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS INC. | 2007-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254917-A1 | INTRACELLULAR RECEPTOR MODULATOR COMPOUNDS AND METHODS | CASR, GRK2, RYR2 | ALDH1A1 4580/4885KDM4E 4073/4885IMPDH2 2686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.